Atreca and Xencor to Develop T-Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target

On February 6, 2023, Atreca, Inc. (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced, as part of their existing strategic collaboration, they have mutually selected the first program combining an Atreca-discovered antibody with Xencor’s XmAb® bispecific Fc domain and a cytotoxic T-cell binding domain (CD3).

Login Or Register To Read Full Story